Returning for its second year, the virtual Epigenetic Therapeutic Targets Summit is the first-ever industry forum dedicated exclusively to the frontier of drug development in epigenetics.
The two-day program will enable you to:
Explore the full spectrum oncological and non-oncological applications of genetic regulation therapeutics that is being investigated to identify new unmet clinical needs that epigenetics could be central to treating.
Evaluate therapeutic targets including LSD1, HDAC, KAT6, H2AThr120 and Non-Coding RNA. This broad array of new and old is bringing some exciting novel insights to this growing meeting of genetic specialists.
Network with the leading biopharma companies and academic institutions in this space with over 4 hours of 1-to-1 networking time, interactive panels and over a dozen keynote presentations.
Delve into the nitty-gritty challenges faced from preclinical to clinical development alongside a group of peers with our new Pre-Conference Workshop. Effectively improve your drug development route and expand your research to identify new opportunities.
If you are investing clinical development resources into epigenetic therapeutics, this online forum has been created with you in mind and will connect you with pharma, biotechs, academia and solution providers accelerating drug candidates towards the goal of a functional cure.
Time: 1:00 pm - 4:00 pm
Conference + Workshop - Drug Developer Pricing: USD 1998.00,
Conference Only - Drug Developer Pricing: USD 1799.00,
Conference + Workshop - Service Provider Pricing: USD 2498.00,
Conference Only - Service Provider Pricing: USD 2199.00,
Conference + Workshop - Academic Pricing: USD 1648.00,
Conference Only - Academic Pricing: USD 1499.00
Speakers: Ellen Filvaroff, Executive Director in Translational Development, Bristol-Myers Squibb, Elisabetta Chiarparin, Director - Medicinal Chemistry, AstraZeneca, Zariana Nikolova, Executive Director, Bristol Myers Squibb, Sylvie Guichard, Senior Director - Translational Science and Biology, Forma Therapeutics, Drew Thompson, Vice President - Molecular Innovation and Pharmaceutical Development, Fulcrum Therapeutics, Chih-Ming Ho, Chief Technology Officer, KYAN Therapeutics, Johnathan Whetstine, Associate Professor of Medicine, Massachusetts General Hospital, Kai He, Assistant Professor of Medicine, Ohio State University Comprehensive Cancer, James Winkler, Vice President - Biology and Translational Medicine, OnKure Inc., Xuedong Liu, Chief Science Officer, OnKure Inc., Torsten Hoffmann, Chief Scientific Officer and Global Head Research and Development , Oryzon Genomics, Tamara Maes, Vice President on the Board of Directors, Oryzon Genomics, Robert Solivia, Head of Drug Discovery, Oryzon Genomics, Thomas Paul, Director - Epigenetics Research, Pfizer, Aundrietta Duncan, Associate Director - Non-Clinical Development, Salarius Pharmaceuticals, Alon Goren, Assistant Professor, University of California San Dieg, Jiuzhou Song, Professor, University of Maryland, Antonello Mai, Professor, University of University of Rome La Sapienza, Nikhil Ghate, Postdoctoral Research Associate, University of Southern California, Sara Martire, Postdoctoral Researcher, University of Texas Southwestern Medical Center, Ari Melnick, Professor, Weill Cornell - Cornell University